Asterias Biotherapeutics (AST) announced that it has completed the enrollment and dosing of five subjects in the first efficacy cohort of its Phase 1/2a study, SCiSTAR, assessing the activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). Each patient was administered 10M AST-OPC1 cells, a dose high enough to show efficacy based on preclinical studies. Top-line six-month data are expected in January 2017.